International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Quality-adjusted progression-free survival analysis of veliparib and carboplatin/paclitaxel compared with chemotherapy alone in patients with newly diagnosed ovarian cancer (VELIA/GOG3005): ancillary analysis of a placebo-controlled, phase 3 randomized trial.
Joseph Lafferty, Angeles Alvarez Secord, Michael Bookman, Robert L Coleman, Minh H Dinh, Nikhil Khandelwal, Rajesh Kamalakar, David Cella
Published: 202510.1016/j.ijgc.2025.102819
Abstract
OBJECTIVE: Veliparib, a poly (adenosine diphosphate-ribose) polymerase inhibitor, was evaluated in a phase 3 trial (VELIA/GOG3005, NCT02470585) among patients with newly diagnosed stage III/IV high-grade serous ovarian cancer. The addition of velipar…
Preview only. Read the full abstract at the source